TERT and neoplasm: Comprehensive genomic profiling by next-generation sequencing (NGS) was obtained to look for targetable genetic variants. Genomic profiling revealed a high tumor mutation burden (TMB) of 27 mutations/Mega bases (Mb) and mutations in the neurofibromatosis 1 (NF1) gene and TERT promoter (Table 1). Programmed cell death Ligand 1 (PD-L1) status was evaluated by immunohistochemistry with an SP142 antibody clone, and PD-L1 expression was detected as 1+ in 2% of tumor cells.